EContra ® EZ (Levonorgestrel) Tablet, 1.5 mg
- Manufacturer
- Afaxys Pharma, LLC | Mylan Laboratories Limited
- Effective date
- 2020-01-20
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 10
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:44:34
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Emergency Contraceptive
One Tablet. One Dose.
What You Need to Know
What is EContra® EZ?
EContra® EZ is emergency contraception that helps prevent pregnancy after birth control failure or unprotected sex. It is a backup method of preventing pregnancy and should not be used as regular birth control.
What EContra® EZ is not.
EContra® EZ will not work if you are already pregnant and will not affect an existing pregnancy. EContra® EZ will not protect you from HIV infection (the virus that causes AIDS) and other sexually transmitted diseases (STDs).
When should I use EContra® EZ?
The sooner you take emergency contraception, the better it works. You should use EContra® EZ within 72 hours (3 days) after you have had unprotected sex.
INDICATIONS & USAGE SECTION
EContra® EZ is a backup or emergency method of birth control you can use when:
- your regular birth control was used incorrectly or failed
- you did not use any birth control method
When not to use EContra® EZ.
EContra® EZ should not be used:
- as a regular birth control method, because it's not as effective as regular birth control.
- if you are already pregnant, because it will not work.
- if you are allergic to levonorgestrel or any other ingredients in EContra® EZ.
When should I talk to a doctor or pharmacist?
Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of EContra® EZ and increase your chance of becoming pregnant. Your doctor may prescribe another form of emergency contraception that may not be affected by these medications.
How does EContra® EZ work?
EContra® EZ is one tablet with levonorgestrel, a hormone that has been used in many birth control pills for several decades. EContra® EZ contains a higher dose of levonorgestrel than birth control pills, but works in a similar way to prevent pregnancy. It works mainly by stopping the release of an egg from the ovary. It is possible that EContra® EZ may also work by preventing fertilization of an egg (the uniting of sperm with the egg) or by preventing attachment (implantation) to the uterus (womb).
How can I get the best results from EContra® EZ?
You have 72 hours (3 days) to try to prevent pregnancy after birth control failure or unprotected sex. The sooner you take EContra® EZ , the better it works.
How effective is EContra® EZ?
If EContra® EZ is taken as directed, it can significantly decrease the chance that you will get pregnant. About 7 out of every 8 women who would have gotten pregnant will not become pregnant.
How will I know EContra® EZ worked?
You will know EContra® EZ has been effective when you get your next period, which should come at the expected time, or within a week of the expected time. If your period is delayed beyond 1 week, it is possible you may be pregnant. You should get a pregnancy test and follow up with your healthcare professional.
Will I experience any side effects?
- some women may have changes in their period, such as a period that is heavier or lighter or a period that is early or late. If your period is more than a week late, you may be pregnant.
- if you have severe abdominal pain, you may have an ectopic pregnancy, and should get immediate medical attention.
- when used as directed, EContra® EZ is safe and effective. Side effects may include changes in your period, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, and breast tenderness.
- if you vomit within 2 hours of taking the medication, call a healthcare professional to find out if you should repeat the dose.
What if I still have questions about EContra® EZ?
If you have questions or need more information, call 1-855-888-2467 or go to
www.afaxys.com, 24 hours a day/7 days a week or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch
Keep out of reach of children:
In case of overdose, get medical help or contact a Poison Control Center right away at 1-800-222-1222.
Do not use if the blister seal is opened.
Store at 20° to 25°C (68° to 77°F).
OTC - ACTIVE INGREDIENT SECTION
Active ingredient: levonorgestrel 1.5 mg
INACTIVE INGREDIENT SECTION
Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, povidone K-25.
SPL UNCLASSIFIED SECTION
If you are sexually active, you should see a healthcare provider for routine checkups. Your healthcare provider will talk to you about and, if necessary, test you for sexually transmitted diseases, teach you about effective methods of routine birth control, and answer any other questions you may have.

Manufactured for:
Afaxys Pharma LLC.
Charleston, SC, 29403, USA.
Manufactured by:
Mylan Laboratories Limited
200012782-000
REVISED: JANUARY 2018

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 50102-111-01
EMERGENCY CONTRACEPTION
EContra®EZ
(Levonorgestrel) Tablet, 1.5 mg
One Tablets Equals One Dose.
Reduces chance of pregnancy after unprotected sex.
The sooner you take it, the more effective it will be
Take as soon as possible within 72 hours (3 days)
after unprotected sex
Will not harm an existing pregnancy
Not for regular birth control.
THIS PACKAGE IS NOT CHILD-RESISTANT
1 Tablet Levonorgestrel 1.5 mg

FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 50102-111-12 | 2023-04-26 | C162847 | 48780-1 | d6a99b39-d3af-a426-e053-dadaa90af4c2 | EContra ® EZ (Levonorgestrel) Tablet, 1.5 mg |
| 50102-111-12 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-d3af-a426-e053-dadaa90af4c2 | EContra ® EZ (Levonorgestrel) Tablet, 1.5 mg |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50102-111-01 | EA - Each | 50102-111 | 874f3fb8-07bf-4f88-98f8-305d46e18d29 | 1 | 2015-03-03 |
| 50102-111-12 | EA - Each | 50102-111 | b0a383b1-eb41-46d0-b404-749a16f30277 | 1 | 2015-03-03 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LEVONORGESTREL | ACTIVE INGREDIENT | 5W7SIA7YZW | 2 | |
| LEVONORGESTREL | ACTIVE MOIETY | 5W7SIA7YZW | 2 | |
| COLLOIDAL SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| POVIDONE K25 | INACTIVE INGREDIENT | K0KQV10C35 | 2 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 2 |
Products#
Every source-derived product name is available through these pages.
- EContra EZ
- levonorgestrel
- SILICON DIOXIDE
- LACTOSE MONOHYDRATE
- MAGNESIUM STEARATE
- POVIDONE K25
- STARCH, CORN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 50102-111 | 50102-111-00, 50102-111-01, 50102-111-12 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LEVONORGESTREL | 5W7SIA7YZW | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| POVIDONE K25 | K0KQV10C35 | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED / ORAL | 300 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INSERT / VAGINAL | 2282 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / SUBLINGUAL | 409 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SOLUTION / ORAL | 1.8 mg/120ml | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| POVIDONE K25 | POVIDONE K25 | K0KQV10C35 | CAPSULE, DELAYED RELEASE / ORAL | 90 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION/ DROPS / ORAL | 90 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 520 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE, DELAYED RELEASE / ORAL | 216 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | PELLET / ORAL | 640 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| POVIDONE K25 | POVIDONE K25 | K0KQV10C35 | GRANULE, FOR SUSPENSION / ORAL | 0.27 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, ORALLY DISINTEGRATING / ORAL | 366 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, COATED / ORAL | 256 mg | ||
| POVIDONE K25 | POVIDONE K25 | K0KQV10C35 | TABLET, COATED / ORAL | 240 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 214 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / ORAL | 1116 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / BUCCAL | 43 mg | ||
| POVIDONE K25 | POVIDONE K25 | K0KQV10C35 | SOLUTION / ORAL | 500 mg/5ml | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | PASTILLE / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 21 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED PELLETS / ORAL | 265 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INHALANT / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SUSPENSION / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 150 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 750 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, DELAYED RELEASE / ORAL | 2313 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE / ORAL | 3990 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, FILM COATED / ORAL | 2000 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, DELAYED RELEASE / ORAL | 2087 mg |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202739-001 | LEVONORGESTREL | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A202739-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-10-31 | f41ea6bd6efb… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d0111568-0dc8-4db8-aa37-8e5c88e0c7f8 | 5752210e-459b-467c-8fda-b5976c07d88e | 2023-04-26 | Warnings | 5752210e-459b-467c-8fda-b5976c07d88e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.